RenovoRx to Showcase TAMP Platform in Pancreatic Cancer Webinar
Event summary
- RenovoRx to participate in JonesTrading webinar on August 13, 2026, discussing pancreatic cancer treatment landscape.
- Webinar features key opinion leaders from Moffitt Cancer Center and AdventHealth Cancer Institute.
- Company highlights TAMP platform and ongoing Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer.
- RenovoCath generated $1.1 million in sales in 2025, with $563,000 in Q1 2026.
The big picture
RenovoRx's participation in this webinar underscores the growing interest in targeted oncology therapies, particularly for pancreatic cancer where treatment options remain limited. The company's focus on expanding its commercial footprint while advancing its Phase III trial positions it at the intersection of immediate revenue generation and long-term therapeutic innovation.
What we're watching
- Clinical Trial Progress
- How the pace of TIGeR-PaC trial enrollment and data readout in mid-to-late 2027 will impact RenovoRx's strategic positioning.
- Commercial Expansion
- Whether RenovoRx can sustain revenue growth through increased adoption of RenovoCath across more cancer centers.
- Regulatory Pathway
- The potential for Orphan Drug Designation to accelerate market exclusivity and commercialization efforts post-approval.
Related topics